The predictive value of BRAF mutations in NSCLC has not been clarified yet, although clinical trials with BRAF and MEK inhibitors in the NSCLC setting are ongoing in order to evaluate the clinical value of this potential biomarker [18–21]. The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.